The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

Learn when hypertrophic cardiomyopathy becomes severe and how a cardiologist guides you through heart transplant evaluation ...

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...

A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...

Researchers at Children's Hospital of Philadelphia (CHOP) reported today that adolescents with hypertrophic cardiomyopathy (HCM) who took mavacamten experienced reduced obstruction, allowing blood to ...

HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...

New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very real, ranging from chest pain and shortness of breath to a racing heart, lightheadedness, and fatigue. But there’s also ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...